NANETS in collaboration with the Society of Nuclear Medicine and Molecular Imaging presents:
PRRT: Background, Published Results, Patient Selection Details, Sequencing of Therapy, and Future Directions

July 23, 2020 – July 23, 2021

Members login here to view the recording

Lisa Bodei, MD, Memorial Sloan Kettering Cancer Center
Jonathan Strosberg, MD, Moffitt Cancer Center

Learning Objectives:

  • Describe the regulatory considerations for the administration of 177Lu-DOTATATE
  • Explain the adjunctive medication options and their appropriate utilization
  • List the impact of PRRT on key endpoints including progression-free survival
  • Identify potential risks of 177Lutetium-dotatate


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the ACCME to provide continuing medical education for physicians.

The CMEsolutions designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component and 60% passing on MOC test, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.